Introduction
Mycosis fungoides (MF) and Sézary syndrome (SS) are the most common forms of cutaneous T-cell lymphoma (CTCL). SS, also referred to as the leukemic phase of erythrodermic CTCL, is caused by a malignant clonal proliferation of central memory T-cells that leads to erythroderma, lymphadenopathy, malignant cells in the peripheral circulation, and immune dysfunction. The current armamentarium of chemotherapeutic and biologic agents is able to palliate but not cure this aggressive non-Hodgkin lymphoma, which has a median survival of 2-4 years. 1 The pathogenic mechanisms underlying CTCL are poorly understood and improved genomic characterization of this disease may shed light on both disease mechanisms and previously unexplored therapeutic targets.
RNA-Seq can be used to obtain global cell transcriptome profiles and thus represents a powerful discovery tool in cancer biology. 2 A major advantage of RNA-Seq over conventional DNA microarray analyses is the ability to identify previously undescribed transcripts, such as lncRNAs. This class of genes is transcribed but not translated and can modulate cellular processes such as epigenetic gene regulation, cell cycle control, and apoptosis. stage MF as well as SS. These data identify candidate lncRNAs with potential roles in the pathogenesis of cancer.
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Methods

Patients
Following informed consent per the Declaration of Helsinki, Sézary patient samples were collected under a protocol approved by the Institutional Review Board at Stanford University Medical Center. All patients had SS by revised staging criteria 5 with clinical stage IVA disease. Patient characteristics are described in Supplemental Methods. The 24 MF tumor samples were collected between 1989-2008 and fall under Exemption 4. All samples were obtained from patients with either clinical stage IIB or III CTCL. All diagnoses were confirmed by a boardcertified dermatopathologist.
Cell Sorting
Peripheral blood mononuclear cells (PBMC) were prepared by Ficoll-Hypaque density-gradient centrifugation. PBMC were stained with fluorochrome-labeled anti-human monoclonal antibodies (Biolegend, Inc.) to CD45 (clone HI30), CD4 (clone RPA-T4), and CD3 (clone HIT3a). T cell receptor (TCR) Vβ clonality was determined with the TCR Vβ Repertoire Kit (Beckman-Coulter). Antibody-stained patient lymphocytes were sorted into CD3+/CD4+/Vβ+ and CD3+/CD4+/Vβ-fractions using an Influx flow cytometer (Becton-Dickinson).
6
Cells and cell Lines
Human CTCL lines MyLa and SeAx were generous gifts from Dr. K. Kalthoft (Aarhus University, Denmark) and were cultured in RPMI with 10% FBS and 200 IU/mL of IL-2. 7, 8 Hut-78 cells were obtained from ATCC. Normal CD4+ T-cells were obtained from healthy volunteers from the Stanford Blood Center; CD4+ T-cells were prepared by Ficoll-Hypaque density-gradient centrifugation followed by CD4+ selection using CD4+ microbeads (Miltenyi).
RNA isolation
Total RNA was isolated from sorted CD3+/CD4+/Vβ+ and CD3+/CD4+/Vβ-lymphocytes (~2-4 x 10 6 ) using Trizol (Invitrogen) followed by DNA removal with the TURBO DNA-free kit (Ambion). RNA integrity was verified using an Agilent 2100 Bioanalyzer. Total RNA from cell lines was prepared using the RNeasy Plus kit (Qiagen). Total RNA extraction from FFPE was performed as previously described. 9 Briefly, multiple 20 μ m sections were deparaffinized, subjected to protease digestion, and then nucleic acid extracted using the RecoverAll Total Nucleic Acid Isolation Kit (Ambion).
Library preparation and sequencing RNA-Seq libraries were prepared with the mRNA Seq Sample Prep Kit (Illumina). mRNA was isolated by polyA selection from 1-2 μ g total RNA, fragmented, and randomly primed for reverse transcription followed by second-strand cDNA synthesis. Following end repair, adenylation of 3' ends, adapter ligation, isolation of ~200 (patient 1) or ~300 bp (patients 2 and 3) cDNA fragments and subsequent PCR amplification, 50 bp (patient 1) or 101 bp (patients 2 and 3) paired-end sequencing reads were obtained using the Illumina HiSeq platform. 3SEQ was performed as described previously. 9 Briefly, oligo-dT-directed reverse transcription generated cDNAs corresponding to 3' ends of poly-adenylated transcripts; following linker ligation, size selection, and PCR amplification, the cDNAs were subjected to deep sequencing on the Illumina GAIIx platform with a raw read length of 36 bp.
Sequence analysis
RNA-Seq reads were aligned to the human reference sequence NCBI build 36.1/hg18 10 with TopHat. 11 Ab initio assembly was performed using Cufflinks 12 and analyzed with Cuffdiff to
For personal use only. on January 8, 2018 . by guest www.bloodjournal.org From determine differential expression. RefSeq and Gencode databases were used as reference annotations to calculate FPKM (Fragments Per Kilobase of transcript per Million mapped reads) values for known transcripts. Scripture 13 and Trinity 14 were used for de novo transcriptome assembly. Scripture assembly was used to categorize transcripts as protein-coding, noncoding, pseudogene, or novel based upon a >1 bp intersection with annotated transcripts from UCSC, 15, 16 Gencode, 17 RefSeq, 18 and Ensembl. 19 3SEQ reads were aligned to hg18 with Bowtie. 20 Read counts for the 3'-most exon of each gene were calculated using a self-developed script (K.Qu). Further details of sequence analysis are described in Supplemental Methods.
Analysis of tissue specificity
Two publicly available RNA-seq datasets from 16 normal human tissues (ArrayExpress #E-MTAB-513 and Gene Expression Omnibus #GSE30554) were used to determine the relative expression of SC-associated lncRNAs and SeCATs. 21 Further description of these datasets and the analysis performed can be found in Supplemental Methods. Relative expression was normalized to average expression in CD3+/CD4+/Vβ-lymphocytes.
Conservation analysis
Basewise phyloP conservation scores and elemental phastCons scores 22 were retrieved based upon transcript coordinates and plotted with fold change using Circos. 23 PhyloCSF 24 was run with ORF finder parameters from ATG to stop and a minimal codon number of 30.
Gene set enrichment analysis (GSEA)
GSEA was performed with a permutation of 1000. Normalized enrichment scores (NES) were calculated to account for differences in gene set size as well as correlations between our dataset and other gene signatures. The false discovery rate (FDR) q-value represents the probability of a false positive finding for a given NES. FDR q-value thresholds of approximately 0.25 are recommended when phenotype permutations are performed.
25
Viral sequence detection
The RINS algorithm was used with default parameters to analyze RNA-Seq data from each patient's SC as well as control lymphocytes.
26
Fusion transcript discovery
The DeFuse algorithm (version 0.4.0) was used with default parameters to analyze RNA-Seq data from each patient's SC as well as control lymphocytes. 27 PCR from cDNA was used to test for the presence of predicted in-frame gene fusions. ChimeraScan was also used to analyze RNA-Seq data with default parameters. 28 cDNA synthesis and PCR cDNA was synthesized from DNase-treated total RNA using the iScript cDNA synthesis kit (BioRad). PCR amplification was performed using the Phusion High-Fidelity PCR kit (New England Biolabs).
Quantitative reverse transcriptase PCR (qRT-PCR) analysis
Quantitative PCR was performed using the Maxima SYBR Green qPCR master mix (Fermentas) and the Stratagene Mx3000P (Agilent Technologies) thermocycler. Samples were run in triplicate and normalized to glyceraldehyde 3-phosphate dehydrogenase (GAPDH). Relative mRNA expression was calculated using the ΔCT method. Primer sequences are listed in Supplemental Table 1 .
Results
RNA-Seq defines a global set of transcriptional aberrations in SS
To characterize RNA expression in SS, we performed paired-end, high-throughput sequencing with the Illumina HiSeq platform on malignant SC as well as patient-matched, normal CD4+ T-lymphocytes purified by flow cytometry directly from the peripheral blood of 3 unrelated individuals with SS ( Figure 1A ). SC were defined as CD3+/CD4+ cells with clonal Vβ expression while patient-matched, CD3+/CD4+ cells with polyclonal Vβ expression isolated in parallel were used as control. We obtained an average of 112 million reads for each sample, >90% of which aligned to the human genome (Supplemental Table 2 ). This depth of coverage is comparable with recent data in human B-cells demonstrating detection of 90% of transcripts. 29 Clonal mRNA expression of the specific malignancy-associated Vβ was seen in sorted malignant populations, compared with polyclonal expression of a diversity of Vβ mRNAs in control lymphocytes ( Figure 1B ), confirming the high degree of purity of malignant and non-malignant cells in each of the populations analyzed.
The majority of transcripts detected in both malignant and non-malignant T cells (72%) corresponded to annotated protein-coding genes ( Figure 1C ). 15% of detected transcripts were unannotated or uncharacterized in the UCSC, Ensembl, RefSeq, and Gencode gene databases and were designated as novel transcripts. Annotated noncoding genes and pseudogenes comprised the remaining 13% of expressed transcripts. These proportions are similar to those obtained recently by RNA-Seq in prostate tissues. 2 We next identified aberrantly expressed transcripts in SS by selecting significantly changed annotated and novel genes in SC compared to control lymphocytes. Annotated protein-coding (57%) and noncoding (24%) transcripts formed the majority of differentially expressed transcripts ( Figure 1D ), followed by novel transcripts (11%) and pseudogenes (8%). These differentially expressed transcripts provided candidates for further analysis.
Cancer-associated gene expression profile in SS
To assess protein-coding gene expression in SS, we assigned sequencing reads to coding transcripts using RefSeq annotations. Reads mapped to 24,888 protein-coding genes (of 32,668) and 19,550 (78.6%) were expressed in all 3 patients. 2,989 genes were differentially expressed in all 3 patients; of these, 525 were commonly up-regulated and 519 were commonly down-regulated ( Figure 2A ). This shared signature of 1044 genes included several entities previously associated with SS, including up-regulation of TNFSF11 (RANKL), PTHLH, EPHA4, [30] [31] [32] [33] To look for evidence of dysregulation of specific signaling pathways in SS, we performed canonical pathway analysis with IPA (Ingenuity Systems, www.ingenuity.com) using genes that ). We also performed pathway analysis on genes that were expressed >2-fold higher in SC than in controls in all 3 patients to identify the pathways that are most robustly increased in SS. We found significant enrichment for genes in the NF-κB signaling cascade (p <2.0 x 10 -4
), consistent with a prior report that NF-κB is constitutively active in CTCL cells. 9, 34 As a complement to IPA, we next performed gene set enrichment analysis (GSEA) using annotated gene sets from the Molecular Signatures Database 25 to determine concordance between significantly changed genes in SS and known gene signatures ( Figure 2C ). This analysis confirmed that the SS gene expression signature is enriched for genes with established importance in cancer as well as phosphatidylinositol and TGFβ signaling.
Differential expression of Sézary cell-associated lncRNAs
To identify differentially expressed lncRNAs in SS, we mapped sequencing reads to annotated noncoding transcripts in the RefSeq and Gencode databases. Reads mapped to 5,099 noncoding transcripts (of 6,629), 3,711 (73%) of which are expressed in all 3 patients. 795
annotated noncoding transcript levels are significantly (p< 0.05) or >2-fold changed in all 3 patients. To enrich for lncRNAs, we removed transcripts from further analysis if they were <200 bp in length, annotated pseudogenes, noncoding transcripts of protein-coding genes, or contained >80% overlap with a known protein-coding transcript. We identified 258 transcripts that passed these filters; of these, 35 were commonly up-regulated and 50 were commonly down-regulated in SC ( Figure 2D ).
To further refine the candidate pool, we required at least a 2-fold change in all 3 patients to enrich for robustly changed lncRNAs. We then reconstructed each of the remaining candidates with Trinity as well as Scripture and removed them from further analysis if the reassembled transcript was incongruent with the existing RefSeq or Gencode annotation. This workflow identified 21 congruently reconstructed lncRNAs with >2-fold differential expression in all 3 patients ( Figure 2E-F) . Expression of these 21 SC-associated lncRNAs was generally detectable in a variety of human tissues ( Figure 2G ). These loci are largely uncharacterized and thus represent candidates for further study in SS.
Viral transcripts are not detected in SS cells
A viral etiology of CTCL has been postulated, but focused searches for human Tlymphotropic virus (HTLV)-1 and human herpesviruses in CTCL have been inconclusive. 35 To determine whether viral transcripts are detectable in the RNA-Seq data from the 3 SS patients, we surveyed reads from SC and control lymphocytes for uniquely viral sequences with an intersection-based approach that we validated using prostate adenocarcinoma cells infected with human papilloma virus-18 (NCBI Sequence Read Archive, SRR073726). 26 Two sequence contigs with viral homology to human immunodeficiency virus and woodchuck hepatitis virus were generated, though subsequent PCR verification and Sanger sequencing confirmed both candidates to be laboratory contaminants (data not shown). Importantly, no sequences with homology to HTLV-1 or other human viruses were identified in either SC or control lymphocytes.
These data therefore do not identify a potential viral etiology of SS.
Recurrent gene fusions are not detected in SS cells
Whole transcriptome sequencing data can be used to detect expressed gene fusions and has led to the discovery of recurrent gene fusions in several cancers. 36, 37 Prior studies have pointed to significant genomic instability in SC; however, recurrent gene fusions have not been identified in CTCL or the majority of T-cell lymphomas in general. 38, 39 To determine whether any gene fusions are expressed in SC or patient-matched normal control cells, we analyzed our paired-end sequencing reads by two orthogonal approaches using the deFuse and ChimeraScan algorithms. 27, 28 The former predicted one putative recurrent gene fusion event that
did not validate by PCR amplification in the corresponding cDNA, while the latter did not nominate any candidate chimeric transcripts (data not shown). Importantly, the depth of coverage in our RNA-Seq data was comparable to that of recent work identifying CIITA rearrangements in Hodgkin lymphoma cell lines using deFuse. 37 While we do not find recurrent gene fusions in SS, we cannot rule out translocations that would not yield fusion transcripts, such as those linking heterologous enhancers to an oncogene.
For
Novel differentially expressed transcripts in SS
To detect previously unidentified transcripts in SS that would have evaded detection by conventional DNA microarray approaches, de novo transcriptome assembly was performed with Scripture and all annotated transcripts were removed. 13 Coding potential scores were calculated for these novel transcripts and compared to the scores of known protein-coding and noncoding transcripts. 40 Interestingly, novel transcripts as a group are generally predicted to be noncoding, a finding that may speak to the relatively recent emergence of ncRNA discovery efforts (Supplemental Figure 1) .
To determine whether these novel transcripts are differentially expressed in SS, we identified candidates that are concordantly changed >2-fold in SC compared to control T-cells in all 3
patients. For this analysis, each transcript was required to contain >1 exon, to be >200 bp in length, and to have at least moderate abundance in either SC or control cells. These steps were aimed at eliminating lowly expressed, single-exon, unreliable fragments generated by RNA-Seq.
We identified 412 novel transcripts that met these criteria and eliminated entities that mapped to multiple genomic loci by BLAST analysis. As transcript reconstruction algorithms frequently overreport isoforms, we further focused our analysis by manually curating the histograms of the read coverage of each transcript to collapse the novel pool into distinct genomic loci. This workflow resulted in 38 candidate novel transcripts that were differentially expressed in SS.
These 38 candidates were then independently reconstructed with Trinity and removed from further analysis if the resulting prediction diverged from the reconstruction generated by Scripture. Recent work comparing the congruence between lncRNA transcripts reconstructed by two assemblers shows that nearly half are identified by only one algorithm, consistent with discrepancies seen in the reconstruction of low abundance protein-coding transcripts. 21 As such, the use of Trinity as an orthogonal assembler to complement transcript predictions made by Scripture was designed to reduce computational artifacts generated by either assembler alone.
This analysis identified 13 novel Sézary cell-associated transcripts (SeCAT) that were congruently reconstructed and differentially expressed in all 3 patients with SS ( Figure 3A and
Supplemental Table 3 ). We translated each SeCAT in all six reading frames and confirmed that none contained homology to any of the 31,912 known protein family domains documented in the Pfam database. 41 To further enrich for bona fide noncoding transcripts in this group, we complemented our initial coding potential analysis with a second, independent assessment of coding capacity using PhyloCSF, 24 an algorithm that uses sequence substitutions within a multispecies nucleotide alignment to determine whether evolutionary pressure exists to preserve Figure 3B) . 21 10 SeCATS are >1000 times more likely to be noncoding than coding by PhyloCSF.
To further characterize these 13 novel transcripts, we analyzed their basewise conservation by phyloP and noted that they display increased conservation across their exons compared to the genome average ( Figure 3C ). SeCAT conservation scores were comparable to the scores of known noncoding transcripts (Supplemental Figure 2) . We then used phastCons to assess for conserved elements within SeCAT mRNAs and identified highly conserved regions in multiple transcripts, consistent with potential functional importance ( Figure 3C ). 42 In contrast to SCassociated lncRNAs that are generally detectable in a wide variety of tissues, SeCATs are largely comprised of CD4+ T-cell or SC-specific transcripts and contain only a few entities with broad tissue expression ( Figure 3D ).
We next sought to study whether the differential SeCAT expression observed in freshly purified SC and normal T-cells from blood also occurred in CTCL cell lines by studying a subset of robustly expressed SeCATs in more depth. We compared expression of SeCAT-1, 5, 6, 7, 9, and 11 in 3 CTCL cell lines (MyLa, SeAx, and Hut-78). RNA levels in these lines were compared to pooled CD4+ T-cells from 3 normal donors. Concordance in the directionality of expression level changes was seen for all SeCATs studied, with the exception of SeCAT-9 ( Figures 3E-F and Supplemental Figure 3A -B). Although SeCAT-9 is up-regulated in the SC of all 3 SS patients, it is expressed at far lower levels in CTCL cell lines than in normal CD4+ T-cells (Supplemental Figure 3B) . Inspection of SeCAT-9 sequencing histograms confirmed upregulation of this 3 exon transcript in SC (Supplemental Figure 3A) , as did qRT-PCR validation in 2 additional freshly sorted SS patient SC (Patients 4 and 5) versus their matched CD4+ Tcells as normal controls (Supplemental Figure 3B ). SeCAT-9 is therefore up-regulated in 5/5 patient SC but down-regulated in all 3 widely used CTCL cell lines, underscoring the potential lack of concordance between expression of a subset of transcripts in these two different contexts. Thus, the altered expression of most, but not all, SeCATs is recapitulated in CTCL cell lines.
Differential expression of Sézary cell-associated lncRNAs and SeCATs in MF
To determine whether differential expression of SC-associated lncRNAs and SeCATs are also present in MF, we performed high-throughput RNA sequencing targeting the 3' end of polyadenylated transcripts (3SEQ) on 24 archival MF tumors ( Figure 4A ). This approach allows quantification of transcript abundance in FFPE tissue despite partial RNA degradation. 9 We
For personal use only. on January 8, 2018. by guest www.bloodjournal.org From obtained an average of 42 million total reads for each sample and an average of 13 million unique mapped reads for each sample. This depth of coverage reflects a 2.5-fold enrichment of unique mapped base pairs compared to a previous report using FFPE samples. 9 While a pure population of patient-matched control cells was obtained for each SS sample studied, procurement of appropriate control tissue for MF specimens was complicated by variations in tumor heterogeneity across samples. To quantify the expression of SC-associated lncRNAs and SeCATs in MF tumors, we normalized the read count of each transcript to the averaged CD3 read count in that sample ( Figure 4B and Supplemental Table 4 Analysis of differentially expressed protein-coding genes produced a core signature of 1044 genes that are concordantly changed in each of the 3 SS patients sequenced. While different groups have previously described expression signatures in SS, the heterogeneity of experimental conditions across studies has obscured a clear consensus. To our knowledge, only one prior study describing a single patient compared SC to patient-matched T-cells using DNA microarray technology. 43 Of the 44 differentially expressed genes in that study, 13 (30%) were significantly changed in all 3 of the SS patients studied here (Supplemental Table 5 ), highlighting the power of sorting cells by this approach. The remaining divergence between datasets may relate to the genetic diversity or to the use of different experimental platforms.
Our analysis also revealed increased expression of several genes that encode transmembrane proteins in all 3 patients (Supplemental Table 6 ). Presenilin-1 is part of the γ-secretase complex that activates Notch1, a potential therapeutic target in CTCL and an important oncogenic pathway in T-cell acute lymphoblastic leukemia. 44 KCNN4 is a calciumregulated potassium channel implicated in T-cell activation and proliferation; inhibition of this channel by TRAM-34 decreases inflammation in murine models of encephalomyelitis and colitis, 45 raising the possibility that it may also reduce SC proliferation. We further note overexpression of PDCD1 in the SC, consistent with previous reports. 46 Given their accessibility to therapeutic antibodies, the transmembrane proteins up-regulated in SS comprise attractive targets for future study.
Prior studies have investigated a potential link between CTCL and viral infections. 35 The absence of viral transcripts in our dataset argues against a viral etiology in SS, though transcriptionally silent viral integration events would escape detection by RNA-Seq. Further, translocations that deregulate oncogene expression by altering its proximity to enhancers, such as the MYC-IGH rearrangement, 39 could escape detection by RNA-Seq yet might be revealed by whole genome sequencing. We also note that recurrent fusion genes occur in a minority of
have not been found. 47 LncRNAs have not previously been reported in association with SS or MF, but have been described in other human cancers and exert functional impacts on diverse cellular processes. [2] [3] [4] To our knowledge, no exhaustive search for cancer-related lncRNAs has been conducted in Tcells. We surveyed our data for differentially expressed annotated lncRNAs and identified 21 that change concordantly and robustly in the 3 SS individuals sequenced. In contrast to SeCATs that display high tissue selectivity, expression of SC-associated lncRNAs was detected in a broad spectrum of normal human tissues. The more ubiquitous expression of these previously annotated lncRNAs likely relates to their identification in non-transformed tissues containing few T-cells and suggests that these transcripts may serve broader biological functions.
These data also identify 13 novel transcripts with differential expression in SS. The SeCATs are largely predicted to be noncoding, though we cannot rule out the possibility that they may share features with short, polycistronic ribosome-associated RNAs (sprcRNAs) or encode small peptides similar to those that regulate Drosophila embryogenesis. 48, 49 Recent large-scale efforts to characterize lncRNAs have identified a number of common features that help distinguish them from protein-coding genes, including higher tissue-specificity, less evolutionary conservation, and lower overall expression. 21 We examined SeCAT coordinates in publicly available RNA-Seq datasets from a variety of normal human tissues and observed that SeCATs display high tissue selectivity. They also demonstrate modest conservation comparable to noncoding transcripts and several contain substantial elemental conservation that may suggest involvement in posttranscriptional regulation or RNA secondary structure. While we focused on higher abundance candidates because they are more experimentally tractable, we do observe lower expression of novel transcripts in general compared to protein-coding genes. These data demonstrate that SeCATs contain features of lncRNAs.
Among the 3 SeCATs not designated by PhyloCSF as highly likely to be noncoding, SeCAT-7 had the highest positive score ( Figure 3B and 3E) , profound conservation at the nucleotide level, and an uncharacterized cDNA clone with a txCdsPredict score of 975 (scores >800 have a 90% chance of being protein-coding). 16 Sequence analysis identified a putative 408 bp ORF that blasts to a hypothetical protein in non-human primates (E-value <1x10 -72 ) (Supplemental Figure   4A ), as well as a confirmed protein in other placental mammals including M. musculus and B.
taurus (E-value <7x10
-57
) and a predicted protein in non-mammals including O. niloticus (tilapia) and T. nigroviridis (pufferfish) (E-value <3x10 -19 ). We also noted a putative 811 bp ORF that
For personal use only. on January 8, 2018 . by guest www.bloodjournal.org From begins with a non-canonical start codon and blasts to a hypothetical protein in P. abelii (orangutan) and N. leucogenys (gibbon) (E-value <3x10 -61 ) (Supplemental Figure 4B) . Analysis of genomic sequence in the nearest non-human primate P. troglodytes verified this preserved open reading frame, although RNA-Seq has not been widely applied to non-human primate tissues and no transcript has yet been described in chimpanzees. We postulate that the smaller ORF may be coding, but note that non-canonical and AUG start codons can coexist at the same genic locus and may encode alternate isoforms with distinct functions as well as regulatory roles. 50 Thus, SeCAT-7 may represent an uncharacterized protein-coding transcript.
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